Market research
REXN Rexahn Pharmaceuticals, Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 3
- Dividend yield
- 0.0%
- Beta
- 0.97
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US7616403090
- Market cap
- 2M
- P/E ratio
- Not available
- Analyst target
- 3
- Dividend yield
- 0.0%
- Beta
- 0.97
About
About Rexahn Pharmaceuticals, Inc
As of November 5, 2020, Rexahn Pharmaceuticals, Inc. was acquired by Ocuphire Pharma, Inc., in a reverse merger transaction. Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma. Rexahn Pharmaceuticals, Inc. has collaboration agreements with Zhejiang Haichang Biotechnology Co., Ltd.; and BioSense Global LLC. The company is headquartered in Rockville, Maryland.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the REXN discussion.
5 years, 4 months ago
Rexahn Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 33.9% below its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.4.
Rexahn Pharmaceuticals, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 28.4% to $-1M since the same quarter in the previous year.
Finally, its free cash flow grew by 52.9% to $-1M since the same quarter in the previous year.
Based on the above factors, Rexahn Pharmaceuticals, Inc gets an overall score of 3/5.